ARL4C and neoplasm: Further, immunoprecipitation assays showed that oxaliplatin treatment decreased ARL4C ubiquitination levels compared to controls, suggesting that tumor cells may attenuate ARL4C degradation to resist oxaliplatin cytotoxicity (Figure 4P).